X Series, R Series, AED Pro, AED 3 BLS Professional Defibrillators, Pro-Padz Radiotransparent Electrode, SurePower
ZOLL MEDICAL CORPORATION · Decision date Dec 27, 2017
What did the FDA approve?
FDA records P160022 as an original PMA application. The recorded decision is approval, dated Dec 27, 2017.
FDA approval order statement
Approval for the X Series Defibrillator Function. The X Series system is indicated for defibrillation on victims of cardiac arrest where there is apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of breathing; and3) Absence of pulseThe X Series system in the Manual mode is indicated for synchronized cardioversion of certain atrial or ventricular arrhythmias. A qualified physician must decide when synchronized cardioversion is appropriate.The X Series system Semiautomatic and Manual mode is indicated for use in early defibrillation programs where the delivery of a defibrillator shock during resuscitation involving CPR, transportation, and definitive care are incorporated into a medically-approved patient care protocol.The X Series system Semiautomatic and Manual mode is indicated for adult and pediatric patients. R Series Defibrillator FunctionThe R Series system is indicated for defibrillation on victims of cardiac arrest where there is apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of breathing; and3) Absence of pulse.The R Series system in the Manual mode is indicated for synchronized cardioversion of certain atrial or ventricular arrhythmias. A qualified physician must decide when synchronized cardioversion is appropriate.The R Series system Semiautomatic and Manual mode is indicated for use in early defibrillation programs where the delivery of a defibrillator shock during resuscitation involving CPR, transportation, and definitive care are incorporated into a medically-approved patient care protocol.The R Series system Semiautomatic and Manual mode is indicated for adult and pediatric patients. AED ProThe AED Pro system is indicated for use on victims of cardiac arrest with apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of breathing; and3) Absence of pulse and other signs of circulation.The device is also indicated for use when ECG monitoring is indicated to evaluate the patients heart rate or ECG morphology. The AED Pro system is indicated for adult and pediatric patients.AED 3 BLSThe ZOLL AED 3 system is indicated for use when a suspected cardiac arrest victim has an apparent lack of circulation as indicated by:1) Unconsciousness;2) Absence of breathing; and3) Absence of pulse and other signs of circulation.The AED 3 system is indicated for adult and pediatric patients. ...
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 27, 2017
Regulatory record facts
- Identifier
- P160022
- Regulatory pathway
- Premarket approval application
- Applicant
- ZOLL MEDICAL CORPORATION
- Product code
- MKJ
- Decision code
- APPR
- Decision date
- Dec 27, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated external defibrillators (non-wearable).
- Applicant
- ZOLL MEDICAL CORPORATION
- Product code
- MKJ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160022 received
Application receipt date recorded by FDA.
P160022 · FDA decision
APPR
P160022/S054 · Related supplement
X Series, R Series, AED Pro, AED 3 BLS Professional Defibrillators, Pro-Padz Radiotransparent Electrode, SurePower
P160022/S056 · Related supplement
ZOLL R Series Monitor/Defibrillator
Timeline entries are records held by MedtechLedger for P160022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ZOLL MEDICAL CORPORATION | PMA supplement | Oct 2, 2026 | FDA | |
ZOLL R Series Monitor/DefibrillatorP160022/S056 | ZOLL MEDICAL CORPORATION | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code MKJ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LIFEPAK 35 monitor/defibrillatorP160026/S076 | Physio-Control, Inc. | PMA supplement | Oct 29, 2026 | FDA |
AED 3 Defibrillator with Uni-PadzP160015/S029 | ZOLL MEDICAL CORPORATION | PMA supplement | Oct 16, 2026 | FDA |
| Physio-Control, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
LIFEPAK 15 monitor/defibrillatorP160026/S073 | Physio-Control, Inc. | PMA supplement | Sep 10, 2026 | FDA |
LIFEPAK 35 monitor/defibrillatorP160026/S069 | Physio-Control, Inc. | PMA supplement | Sep 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ZOLL MEDICAL CORPORATION
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 269 & 271 Mill Rd., Chelsmford, MA, 01824
Sources and methodology
- Original FDA record: P160022
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


